sitagliptin + saxagliptin

sitagliptin + saxagliptin" is a hypothetical combination of two dipeptidyl peptidase-4 (DPP-4) inhibitors, both used for the treatment of type 2 diabetes mellitus. Each drug individually inhibits the DPP-4 enzyme, thereby prolonging the action of incretin hormones (GLP-1 and GIP), which increases insulin secretion and decreases glucagon secretion, leading to reduced hepatic glucose production[1][3][8]. There is no evidence or regulatory approval for a fixed-dose combination product containing both sitagliptin and saxagliptin; current clinical practice does not support combining two DPP-4 inhibitors due to lack of additive benefit and increased risk without additional efficacy[9].

Other names

sitagliptin plus saxagliptin